Research

Hormonal

GLP-1 receptor agonists provide renoprotective effects by slowing eGFR decline and reducing albuminuria in patients with type 2 diabetes and chronic kidney disease.

If you have diabetes and kidney issues, GLP-1 medications can help protect your kidneys and heart, not just your blood sugar. This protection happens through multiple mechanisms, including reducing inflammation and improving blood flow to the kidneys. However, gastrointestinal side effects are common and may require dose adjustments or management strategies.

StrongSupportsVERY_HIGH confidence
The FLOW trial... established that semaglutide had direct renoprotective effects that lowered the risk of kidney and heart-related death.
Megha Pawar et al. · BioMed Target Journal · 2025

Why this rating

Supported by the FLOW trial, a major outcome trial cited in the text.

Source

GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives

Megha Pawar et al. · BioMed Target Journal · 2025

DOI 10.59786/bmtj.322

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →